GP
NAGE

GLG Partners’s Niagen Bioscience NAGE Stock Holding History

GLG Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$97K Buy
+16,473
New +$89K ﹤0.01% 417

Other funds holding NAGE

IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
PM
Precept Management Dallas, Texas $126M AUM 36.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

GLG Partners's NAGE Position: Q4 2017 in Review

GLG Partners opened a new position in Niagen Bioscience (NAGE) in Q4 2017: 16,473 shares worth $97K. The stake represents ﹤0.01% of the portfolio and ranks #417 among its holdings.

53 funds tracked by Wall St. Rank hold NAGE as of Q4 2017.

  • GLG Partners held 16,473 shares of Niagen Bioscience worth $97K as of Q4 2017.
  • Niagen Bioscience was a new GLG Partners position in Q4 2017.
  • Niagen Bioscience made up ﹤0.01% of GLG Partners's portfolio in Q4 2017, its #417 holding.
  • 53 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.